Resource Summary Report

Generated by dkNET on Sep 1, 2026

Kasumi-1

RRID:CVCL_0589
Type: Cell Line

Proper Citation

RRID:CVCL_0589

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0589

Proper Citation: RRID:CVCL_0589

Description: Cell line Kasumi-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Childhood acute myeloid leukemia with maturation

Defining Citation: PMID:2018839, PMID:8558913, PMID:9738977, PMID:10739008, PMID:11226526, PMID:11753612, PMID:12111653, PMID:15621809, PMID:15843827, PMID:16408098, PMID:16523483, PMID:18292219, PMID:18385756, PMID:20164919, PMID:20227111, PMID:20922763, PMID:22068913, PMID:22460905, PMID:23955599, PMID:24211243, PMID:24976338, PMID:25485619, PMID:25877200, PMID:25984343, PMID:26589293, PMID:27397505, PMID:28109323, PMID:28196595, PMID:29491412, PMID:30285677, PMID:30629668, PMID:30894373, PMID:31068700, PMID:31160637, PMID:31978347, PMID:32180206, PMID:35839778, PMID:36982453

Comments: Karyotypic information: Some chromosome Y fragments are integrated into other chromosomes (PubMed=18292219)., Karyotypic information: Has lost chromosome Y (PubMed=2018839)., Population: Japanese., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Kasumi-1

Synonyms: KASUMI-1, Kasumi 1, KASUMI1, Kasumi1

Cross References: BTO:BTO_0004136, CLO:CLO_0007068, CLO:CLO_0007069, EFO:EFO_0006607, MCCL:MCC:0000264, CLDB:cl2998, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-2724, BCRC:60505, BCRJ:0305, BioGRID_ORCS_Cell_line:1617, BioSample:SAMN01821572, BioSample:SAMN01821642, BioSample:SAMN01821688, BioSample:SAMN03473161, BioSample:SAMN10988020, cancercelllines:CVCL_0589, CCRID:3101HUMSCSP5015, CCRID:3101HUMTCHu202, CCRID:4201HUM-CCTCC00296, CCTCC:GDC0296, Cell_Model_Passport:SIDM01005, ChEMBL-Cells:CHEMBL3307835, ChEMBL-Targets:CHEMBL613988, CLS:300226, Cosmic:787441, Cosmic:907275, Cosmic:975258, Cosmic:981579, Cosmic:987968, Cosmic:1012076, Cosmic:1078725, Cosmic:1149336, Cosmic:1181600, Cosmic:1451847, Cosmic:1476423, Cosmic:1509202, Cosmic:1516633, Cosmic:1524831, Cosmic:1623636, Cosmic:1779131, Cosmic:2089650, Cosmic:2131540, Cosmic:2306211, Cosmic:2690663, Cosmic:2701742, Cosmic:2750859, Cosmic-CLP:907275, DepMap:ACH-000263, DSMZ:ACC-220, DSMZCellDive:ACC-220, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5_SSTAR:10788-110H5, GDSC:907275, GEO:GSM236785, GEO:GSM236821, GEO:GSM482490, GEO:GSM506744, GEO:GSM506867, GEO:GSM506973, GEO:GSM743409, GEO:GSM887197, GEO:GSM888270, GEO:GSM955189, GEO:GSM955190, GEO:GSM955191, GEO:GSM1374590, GEO:GSM1446745, GEO:GSM1669979, GEO:GSM2716744, GEO:GSM2716745, GEO:GSM2716746, GEO:GSM2716747, GEO:GSM4254129, IARC_TP53:21428, IZSLER:BS TCL 242, JCRB:JCRB1003, JCRB:NIHS0235, LiGeA:CCLE_291, LINCS_LDP:LCL-1055, PharmacoDB:KASUMI1_733_2019, PRIDE:PXD000185, PRIDE:PXD030304, Progenetix:CVCL_0589, PubChem_Cell_line:CVCL_0589, Wikidata:Q38098914

ID: CVCL_0589

Record Creation Time: 20220427T220657+0000

Record Last Update: 20260829T234401+0000

Ratings and Alerts

No rating or validation information has been found for Kasumi-1.

Warning: Discontinued: JCRB; NIHS0235
Karyotypic information: Some chromosome Y fragments are integrated into other chromosomes (PubMed=18292219)., Karyotypic information: Has lost chromosome Y (PubMed=2018839)., Population: Japanese., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 364 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Dutta S, et al. (2026) MMP9 drives cancer invasion by mediating integrin membrane trafficking and stabilization. The FEBS journal.

Pereira-Martins DA, et al. (2026) ??Np73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. Cell reports. Medicine, 102540.

Inthanachai T, et al. (2026) Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy. Immuno-oncology technology, 29, 101584.

Shaum JB, et al. (2026) High-throughput ligand diversification to discover chemical inducers of proximity. Nature chemical biology.

Saad J, et al. (2026) Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia. Molecular oncology, 20(2), 389.

Waclawiczek A, et al. (2026) Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. Cell stem cell, 33(6), 982.

Liu Q, et al. (2026) DHX15 affects AML1-ETO9a splicing together with HNRNPL, RBM33 in AML1-ETO-positive acute myeloid leukaemia. British journal of haematology.

Hofstetter M, et al. (2026) Enhancement of CD117-Targeted Bispecific T-cell Engagement by CD33-Targeted Bispecific T-cell Costimulation in Acute Myeloid Leukemia. Cancer research communications, 6(4), 946.

Sheth AS, et al. (2025) PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid Leukemia. Cancer research communications, 5(4), 648.

Zhang N, et al. (2025) Jab1 promotes immune evasion and progression in acute myeloid leukemia models under oxidative stress. The Journal of clinical investigation, 135(20).

Leesang TE, et al. (2025) Retinoic acid and ascorbate synergize to suppress myeloid leukemia via TET2 activation. Cell reports, 44(10), 116379.

Balasundaram N, et al. (2025) A novel strategy to target metabolic dependencies in acute myeloid leukemia. Cell death & disease, 16(1), 792.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Su Y, et al. (2025) Loss of SETD8 Impairs Mitochondrial Homeostasis to Suppress Leukemia Stem Cell Function in t(8;21) Acute Myeloid Leukemia. Cancer research, 85(21), 4122.

Schmitt N, et al. (2025) The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. Nature communications, 16(1), 7793.

Shang K, et al. (2025) CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models. Cell reports. Medicine, 6(6), 102148.

Arroyo-Berdugo Y, et al. (2025) Exploiting PP2A dependent and independent effects of forskolin for therapeutic targeting of KMT2A (MLL)-rearranged acute leukaemia. British journal of pharmacology.

Zhou Y, et al. (2025) Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e11573.

Esdar C, et al. (2025) M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer. Molecular cancer therapeutics, 24(7), 1040.

Zhou RW, et al. (2025) Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens. Cell.